Laboratorios Farmalán, S.A.
PolandAll drugs from this manufacturer
-
The medicine is used in postmenopausal women for the treatment of a certain type of breast cancer (locally advanced or metastatic) that has estrogen receptors. It may also be used in combination with another medicine (palbociclib) in women with a similar type of cancer, and in premenopausal women – in combination with an additional medicine.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage fulvestrant 250 mg/5 ml ATC: L02BA03
-
The medicine is used in postmenopausal women for the treatment of a certain type of breast cancer (locally advanced or metastatic) that is hormone receptor-positive. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without HER2 overexpression).
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage fulvestrant 250 mg/5 ml ATC: L02BA03
-
The medicine is used in women with a certain type of breast cancer that is estrogen receptor-positive or hormone receptor-positive, which is locally advanced or has metastasized. It may be used as a monotherapy or in combination with another medicine (palbociclib).
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage fulvestrant 250 mg/5 mL ATC: L02BA03
-
The medicine is used to treat postmenopausal women with a specific type of advanced or metastatic breast cancer that is hormone receptor-positive. It may also be used in combination with another medicine (palbociclib) in women with hormone receptor-positive breast cancer (without overexpression of the HER2 receptor).
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage fulvestrant 250 mg/5 ml ATC: L02BA03
-
The medicine is used in postmenopausal women for the treatment of a specific type of breast cancer (locally advanced or metastatic). It may also be used in combination with another medicine (palbociclib) in women with a similar type of breast cancer who have not yet reached menopause.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage fulvestrant 250 mg/5 ml ATC: L02BA03
-
The medicine is used in postmenopausal women for the treatment of a certain type of breast cancer (estrogen receptor-positive) that is locally advanced or has metastasized. It may also be used in combination with another medicine (palbociclib) in women with hormone receptor-positive breast cancer.
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage fulvestrant 250 mg/5ml ATC: L02BA03
-
This medicine is used to treat postmenopausal women with a certain type of breast cancer (locally advanced or metastatic) that has estrogen receptors. It may also be used in combination with palbociclib in women with hormone receptor-positive breast cancer (without overexpression of the HER2 receptor).
Dosage form: solution for injection in ampoule-syringe
Active substance Dosage fulvestrant 250 mg/5 ml ATC: L02BA03
-
The medicinal product is used in adult men as replacement therapy for the treatment of conditions resulting from testosterone deficiency (male hypogonadism).
Dosage form: solution for injection
Active substance Dosage testosterone undecanoate 250 mg/ml ATC: G03BA03
-
The medicine is used to treat women with a certain type of breast cancer (with the presence of estrogen or hormonal receptors) that is locally advanced or has metastasized. It may be administered as monotherapy or in combination with palbociclib.
Dosage form: solution for injection
Active substance Dosage fulvestrant No input provided ATC: L02BA03